Previous Page  5 / 38 Next Page
Information
Show Menu
Previous Page 5 / 38 Next Page
Page Background

Prostate Cancer Clinical States

Aggarwal RR, et al. Oncology (Williston Park). 2017;31:467-474.

Radiographic

Metastases:

ADT resistant

Prechemo

Sipuleucel-T

Abiraterone

Enzalutamide

Radium-223

Recurrent After Initial Hormonal Therapy

Hormone Sensitive

Rising PSA

Salvage regimen,

ADT, or no

therapy

Radiographic

Metastases:

ADT resistant

First-line Chemo

Docetaxel

Localized

Disease

Local therapy

or no therapy

Rising PSA:

ADT resistant

No standard

of care

Overt

Metastases

ADT +

docetaxel or

abiraterone

Radiographic

Metastases:

ADT resistant

Postchemo

Cabazitaxel

Abiraterone

Enzalutamide

Radium-223